Jae‐Yong Kwak
YOU?
Author Swipe
View article: Impact of Cell-of-Origin and MYC/BCL2 Status on the Risk of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma
Impact of Cell-of-Origin and MYC/BCL2 Status on the Risk of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma Open
MYC/BCL2 DE and synchronous bilateral breast involvement may help identify patients at higher risk for CNS relapse. Further studies are warranted.
View article: Advances in PCL, PLA, and PLGA-Based Technologies for Anticancer Drug Delivery
Advances in PCL, PLA, and PLGA-Based Technologies for Anticancer Drug Delivery Open
Biodegradable polymers such as Polycaprolactone (PCL), Polylactic acid (PLA), and Poly(lactic-co-glycolic acid) (PLGA) are attracting attention as key platforms for anticancer drug delivery systems due to their excellent biocompatibility a…
View article: Development of Monoclonal Antibody Application in Cancer Therapy: The Roles of ADCC, CDC, ADCP, and ADC
Development of Monoclonal Antibody Application in Cancer Therapy: The Roles of ADCC, CDC, ADCP, and ADC Open
View article: Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient
Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient Open
Pembrolizumab, an immune checkpoint inhibitor (ICI) targeting the programmed cell death protein 1 (PD-1) receptor on T cells, enhances the immune system’s ability to recognize and attack cancer cells. However, immune-related adverse events…
View article: Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial Open
Potential synergism between Bruton’s tyrosine kinase (BTK) inhibitor and lenalidomide in treating aggressive B-cell lymphoma has been suggested. Here, the authors report a single-arm phase II clinical trial of combination of acalabrutinib,…
View article: Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study Open
Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).Methods: This multi…
View article: Risk stratification for early mortality in newly diagnosed acute promyelocytic leukemia: a multicenter, non-selected, retrospective cohort study
Risk stratification for early mortality in newly diagnosed acute promyelocytic leukemia: a multicenter, non-selected, retrospective cohort study Open
Introduction Despite the current effective treatments for acute promyelocytic leukemia (APL), early mortality (EM), defined as death within 30 days of presentation, is a major hurdle to long-term survival. Methods We performed a multicente…
View article: A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Open
The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.
View article: Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas Open
View article: S229: PROPHYLACTIC EFFICACY OF INTRATHECAL VERSUS INTRAVENOUS METHOTREXATE FOR CNS RELAPSE IN HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA: A PHASE III RANDOMIZED, CONTROLLED STUDY
S229: PROPHYLACTIC EFFICACY OF INTRATHECAL VERSUS INTRAVENOUS METHOTREXATE FOR CNS RELAPSE IN HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA: A PHASE III RANDOMIZED, CONTROLLED STUDY Open
Background: The outcome of patients with central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL) is poor, with a median survival of only 2 to 7 months. Intrathecal methotrexate (ITMTX) has traditionally been used, alt…
View article: Combination of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B cell non‐Hodgkin lymphoma
Combination of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B cell non‐Hodgkin lymphoma Open
Introduction: Previous studies have shown that combination of acalabrutinib with rituximab and lenalidomide has a synergistic effect in killing NHL cells. We hypothesized that the R2A regimen would show satisfying efficacy for relapsed/ref…
View article: TREATMENT PATTERNS IN PATIENTS WITH MANTLE CELL LYMPHOMA: UPDATED REPORT OF THE ASIA‐PACIFIC MULTINATIONAL RETROSPECTIVE REGISTRY STUDY
TREATMENT PATTERNS IN PATIENTS WITH MANTLE CELL LYMPHOMA: UPDATED REPORT OF THE ASIA‐PACIFIC MULTINATIONAL RETROSPECTIVE REGISTRY STUDY Open
Introduction: We conducted a multinational, multicenter retrospective registry study to better define the treatment patterns and survival outcomes of newly diagnosed patients with mantle cell lymphoma (MCL) in the Asia-Pacific region. Meth…
View article: OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: RESULTS FROM KOREAN MULTICENTER COHORT
OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: RESULTS FROM KOREAN MULTICENTER COHORT Open
Introduction: Hodgkin lymphoma (HL) is a rare disease especially in Asian known to have good prognosis. However, in elderly patients (pts), due to comorbidities and poorer tolerance to treatment, the survival rate is not as good as in youn…
View article: Supplementary Figure 1C from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 1C from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (c) Radotinib 300 mg bid (n = 79 patients with evaluable molecular data at 3 months).
View article: Supplementary Figure 1 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 1 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS).EMR at 3 months.
View article: Supplementary Figure 2 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 2 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Major molecular response by 12 months, by Sokal risk group. bid, twice daily; MMR, major molecular response (defined as BCR-ABL1 transcript level {less than or equal to}0.1% [MR3.0]); qd, daily.
View article: Supplementary Methods, Supplementary Figure Legends, Supplementary Table from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Methods, Supplementary Figure Legends, Supplementary Table from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Supplementary Methods, Supplementary Figure Legends, Supplementary Table
View article: Supplementary Figure 3B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 3B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Kaplan-Meier estimated progression-free survival (PFS) in the intention-to-treat population
View article: Supplementary Figure 1D from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 1D from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (d) Radotinib 400 mg bid (n = 79 patients with evaluable molecular data at 3 months).
View article: Supplementary Figure 2 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 2 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Major molecular response by 12 months, by Sokal risk group. bid, twice daily; MMR, major molecular response (defined as BCR-ABL1 transcript level {less than or equal to}0.1% [MR3.0]); qd, daily.
View article: Data from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Data from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This s…
View article: Supplementary Figure 1B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 1B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (b) Imatinib 400 mg qd (n = 78 patients with evaluable molecular data at 3 months).
View article: Supplementary Figure 3B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 3B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Kaplan-Meier estimated progression-free survival (PFS) in the intention-to-treat population
View article: Supplementary Figure 1 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 1 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS).EMR at 3 months.
View article: Supplementary Methods, Supplementary Figure Legends, Supplementary Table from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Methods, Supplementary Figure Legends, Supplementary Table from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Supplementary Methods, Supplementary Figure Legends, Supplementary Table
View article: Data from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Data from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This s…
View article: Supplementary Figure 3A from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 3A from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Kaplan-Meier (A) estimated overall survival (OS)
View article: Supplementary Figure 1C from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 1C from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (c) Radotinib 300 mg bid (n = 79 patients with evaluable molecular data at 3 months).
View article: Supplementary Figure 1D from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 1D from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (d) Radotinib 400 mg bid (n = 79 patients with evaluable molecular data at 3 months).
View article: Supplementary Figure 3A from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Supplementary Figure 3A from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Open
Kaplan-Meier (A) estimated overall survival (OS)